 All patients included in the protocol ACTFRIE, will be asked to participate in the study of tolerance. They will receive pioglitazone at a dose of 45 mg per day, until the data on the effectiveness or otherwise of this treatment, its side effects in patients with Friedreichs ataxia are known by the results of ACTFRIE testing approximately April 2014. 